Clinical Pharmacokinetics

, Volume 19, Issue 5, pp 341–358 | Cite as

Therapeutic Drug Monitoring of Phenytoin Rationale and Current Status

  • Marc Levine
  • Tom Chang
Leading Article


Phen Therapeutic Drug Monitoring Free Concentration Bayesian Forecast Phcn 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen JP, Ludden TM, Burrow SR, Clementi WA, Stavchansky SA. Phenytoin cumulation kinetics. Clinical Pharmacology and Therapeutics 26: 445–448, 1979PubMedGoogle Scholar
  2. Anavekar SN, Saunders RH, Wardell WM, Shoulson I, Emmings FG, et al. Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations. Clinical Pharmacology and Therapeutics 24: 629–637, 1978PubMedGoogle Scholar
  3. Argyle JC, Kinniburgh DW, Costa R, Jennison T. Evaluation of an ultrafiltration-fluorescence polarization immunoassay for monitoring unbound phenytoin. Therapeutic Drug Monitoring 6: 117–120, 1984PubMedCrossRefGoogle Scholar
  4. Baird-Lambert J, Manglick MP, Wall M, Buchanan N. Identifying patients who might benefit from free phenytoin monitoring. Therapeutic Drug Monitoring 9: 134–138, 1987PubMedCrossRefGoogle Scholar
  5. Barth N, Alvan G, Borga O, Sjoqvist F. Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clinical Pharmacokinetics 1: 444–452, 1976PubMedCrossRefGoogle Scholar
  6. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clinical Pharmacology and Therapeutics 31: 301–304, 1982PubMedCrossRefGoogle Scholar
  7. Bauer LA, Blouin RA. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients. Clinical Pharmacokinetics 8: 545–549, 1983PubMedCrossRefGoogle Scholar
  8. Beal SL. Computation of the explicit solution to the Michaelis-Menten equation. Journal of Pharmacokinetics and Biopharmaceutics 11: 641–657, 1983PubMedCrossRefGoogle Scholar
  9. Beardsley RS, Freeman JM, Appel FA. Anticonvulsant scrum levels are useful only if the physician appropriately uses them: an assessment of the impact of providing serum level data to physicians. Epilepsia 24: 330–335, 1983PubMedCrossRefGoogle Scholar
  10. Beck DE, Farringer JA, Ravis WR, Robinson CA. Accuracy of three methods for predicting concentrations of free phenytoin. Clinical Pharmacy 6: 888–894, 1987PubMedGoogle Scholar
  11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307–310, 1986PubMedCrossRefGoogle Scholar
  12. Blaser KU, Vo>zeh S, Landolt H, Kaufmann G, Romppainen J, et al. Intravenous phenytoin: a loading scheme for desired concentrations. Annals of Internal Medicine 110: 1029–1031, 1989PubMedGoogle Scholar
  13. Booker HE, Darcey B. Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 14: 177–184, 1973PubMedCrossRefGoogle Scholar
  14. Borofsky LG, Louis S, Kutt H, Roginsky M. Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children. Journal of Pediatrics 81: 995–1002, 1972PubMedCrossRefGoogle Scholar
  15. Boston Collaborative Drug Surveillance Program. Diphenylhydantoin side effects and serum albumin levels. Clinical Pharmacology and Therapeutics 14: 529–532, 1973Google Scholar
  16. Bouma PAD, Peters ACB, Arts RJHM, Stijnen T, Van Rossum J. Discontinuation of antiepileptic therapy: a prospective study in children. Journal of Neurology, Neurosurgery, and Psychiatry 50: 1579–1583, 1987PubMedCrossRefGoogle Scholar
  17. Bryson SM, Al-Lanqawi Y, Kelman AW, Whiting B. Comparison of a Bayesian forecasting technique with a new method for estimating phenytoin dose requirements. Therapeutic Drug Monitoring 10: 80–84, 1988PubMedGoogle Scholar
  18. Buchthal F, Svensmark OP, Schiller PJ. Clinical and electroen-cephalographic correlations with serum levels of diphenylhydantoin. Archives of Neurology (Chicago) 2: 624–630, 1960CrossRefGoogle Scholar
  19. Burton ME, Vasko MR, Brater DC. Comparison of drug dosing methods. Clinical Pharmacokinetics 10: 1–37, 1985PubMedCrossRefGoogle Scholar
  20. Bussey HI, Hoffman EW. A prospective evaluation of therapeutic drug monitoring. Therapeutic Drug Monitoring 5: 245–248, 1983PubMedCrossRefGoogle Scholar
  21. Cacek AT. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids and food. Therapeutic Drug Monitoring 8: 166–171, 1986PubMedCrossRefGoogle Scholar
  22. Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years: a prospective study. New England Journal of Medicine 318: 942–946, 1988PubMedCrossRefGoogle Scholar
  23. Callaghan N, Kenny RA, O’Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 48: 639–644, 1985PubMedCrossRefGoogle Scholar
  24. Chiba K, Ishizaki T, Miura H, Minagawa K. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. Journal of Pediatrics 96: 479–484, 1980PubMedCrossRefGoogle Scholar
  25. Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants: state of the art. Clinical Pharmacokinetics 18: 318–328, 1990PubMedCrossRefGoogle Scholar
  26. Cobos JE. High-dose phenytoin in the treatment of refractory epilepsy. Epilepsia 28: 111–114, 1987PubMedCrossRefGoogle Scholar
  27. Coleman RW, Krewsun I, Kelber RL. Single feedback Bayesian forecasts with free and total phenytoin concentrations. Clinical Pharmacokinetics 9 (Suppl. 1): 90–92, 1984CrossRefGoogle Scholar
  28. Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE. Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose. European Journal of Clinical Pharmacology 32: 141–148, 1987PubMedCrossRefGoogle Scholar
  29. Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clinical Pharmacokinetics 3: 39–57,. 1978PubMedCrossRefGoogle Scholar
  30. DeMonaco HJ, Lawless LM. Variability of phenytoin protein binding in epileptic patients. Archives of Neurology 40: 481–483, 1983PubMedCrossRefGoogle Scholar
  31. Dodson WE. Nonlinear kinetics of phenytoin in children. Neurology 32: 42–48, 1982PubMedCrossRefGoogle Scholar
  32. Feeley M, Duggan B, O’Callaghan M, Callaghan N. The therapeutic range for phenytoin — a reappraisal. Irish Journal of Medical Science 2: 44–49, 1979CrossRefGoogle Scholar
  33. Feldman RG, Pippenger CE. The relation of anticonvulsant drug levels to complete seizure control. Journal of Clinical Pharmacology 16: 51–59, 1976PubMedGoogle Scholar
  34. Flint N, Lopez LM, Robinson JD, Williams C, Salem RB. Comparison of eight phenytoin dosing methods in institutionalized patients. Therapeutic Drug Monitoring 7: 74–80, 1985PubMedCrossRefGoogle Scholar
  35. Froscher W, Eichelbaum M, Gugler R, Hildenbrand G, Penin H. A prospective randomized trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. Journal of Neurology 224: 193–201, 1981PubMedCrossRefGoogle Scholar
  36. Gerber N, Wagner JG. Explanation of dose dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Research Communications in Chemical Pathology and Pharmacology 3: 455–466, 1972PubMedGoogle Scholar
  37. Godley PJ, Ludden TM, Clementi WA, Godley SE, Ramsey RR. Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations. Clinical Pharmacy 6: 634–639, 1987PubMedGoogle Scholar
  38. Grasela TH, Sheiner LB, Rambeck B, Boenigk HE, Dunlop A, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clinical Pharmacokinetics 8: 355–364, 1983PubMedCrossRefGoogle Scholar
  39. Graves NM, Leppik IE, Termond E, Taylor JW. Phenytoin clearances in a compliant population: description and application. Therapeutic Drug Monitoring 8: 427–433, 1986PubMedCrossRefGoogle Scholar
  40. Haerer AF, Grace JB. Studies of anticonvulsant levels in epileptics. Acta Neurologica Scandinavica 45: 18–31, 1969PubMedCrossRefGoogle Scholar
  41. Ioannides-Demos LL, Horne MK, Tong N, Wodak J, Harrison PM, et al. Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory-care epilepsy clinic. American Journal of Hospital Pharmacy 45: 1549–1551, 1988PubMedGoogle Scholar
  42. Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RFW. Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate — the predictive value of plasma albumin concentration. British Journal of Clinical Pharmacology 27: 843–849, 1989PubMedCrossRefGoogle Scholar
  43. Jung D, Powell JR, Walson P, Perrier D. Effect of dose on phenytoin absorption. Clinical Pharmacology and Therapeutics 28: 479–485, 1980PubMedCrossRefGoogle Scholar
  44. Killilea T, Coleman R, Ludden T, Peck CC, Rose D. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Therapeutic Drug Monitoring 11: 455–462, 1989PubMedGoogle Scholar
  45. Kilpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of unbound phenytoin in the management of epilepsy. British Journal of Clinical Pharmacology 17: 539–546, 1984PubMedCrossRefGoogle Scholar
  46. Knott C, Hamshaw-Thomas A, Reynolds F. Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. British Medical Journal 284: 13–16, 1982PubMedCrossRefGoogle Scholar
  47. Koch-Weser J. The serum level approach to individualization of drug dosage. European Journal of Clinical Pharmacology 9: 1–8, 1975PubMedCrossRefGoogle Scholar
  48. Koike Y, Magnusson A, Steiner E, Rane A, Sjöqvist F. Ultrafiltration compared with equilibrium dialysis in the determination of unbound phenytoin in plasma. Therapeutic Drug Monitoring 7: 461–465, 1985PubMedCrossRefGoogle Scholar
  49. Koup JR, Gibaldi M, Godolphin W. Single point estimation of phenytoin dosing: a reappraisal. Research Communications in Chemical Pathology and Pharmacology 34: 231–239, 1981PubMedGoogle Scholar
  50. Kutt H. Phenytoin: relation of plasma concentration to seizure control. In Woodbury et al. (Eds) Antiepileptic drugs, pp. 241–246, Raven Press, New York, 1982Google Scholar
  51. Kutt H, Penry K. Usefulness of blood levels of antiepileptic drugs. Archives of Neurology 31: 283–288, 1974PubMedCrossRefGoogle Scholar
  52. Kutt H, Winters W, Kokenge R, McDowell F. Diphenylhydantoin metabolism, blood levels and toxicity. Archives of Neurology 11: 642–648, 1964PubMedCrossRefGoogle Scholar
  53. Lambie DG, Nanda RN, Johnson RH, Shakir RA. Therapeutic and pharmacokinetic effects of increasing phenytoin in chronic epileptics on multiple drug therapy. Lancet 2: 386–389, 1976PubMedCrossRefGoogle Scholar
  54. Levine M, McCollom R, Chang T, Orr J. Evaluation of serum phenytoin monitoring in an acute care setting. Therapeutic Drug Monitoring 10: 50–57, 1988PubMedGoogle Scholar
  55. Levine M, Orr J, Chang T. Evaluation of a nomogram for estimating the rate of phenytoin accumulation. Therapeutic Drug Monitoring 9: 166–170, 1987aPubMedCrossRefGoogle Scholar
  56. Levine M, Orr J, Chang T. Interindividual variation in the extent and rate of phenytoin accumulation. Therapeutic Drug Monitoring 9: 171–176, 1987bPubMedCrossRefGoogle Scholar
  57. Levy RH. Monitoring free drug levels: determination of free concentration versus free fraction. Therapeutic Drug Monitoring 5: 243–244, 1983PubMedCrossRefGoogle Scholar
  58. Ludden TM, Allen JP, Schneider LW, Stavchansky SA. Rate of phenytoin accumulation in man: a simulation study. Journal of Pharmacokinetics and Biopharmaceutics 6: 399–415, 1978PubMedCrossRefGoogle Scholar
  59. Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, et al. Individualization of phenytoin dosage regimens. Clinical Pharmacology and Therapeutics 21: 287–293, 1977PubMedGoogle Scholar
  60. Ludden TM, Beal SL, Peck CC, Godley PJ. Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration. Clinical Pharmacy 5: 580–585, 1986PubMedGoogle Scholar
  61. Lund L. Effects of phenytoin in patients with epilepsy in relation to its concentration in plasma. In Davies & Prichard (Eds) Biological effects of drugs in relation to their plasma concentrations, pp. 227–238, University Park Press, London, 1973Google Scholar
  62. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels: a prospective three year study in ambulant patients with generalized epileptic seizures. Archives of Neurology 31: 289–294, 1974PubMedCrossRefGoogle Scholar
  63. Lund L, Berlin A, Lunde PKM. Plasma protein binding of diphenylhydantoin in patients with epilepsy: agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clinical Pharmacology and Therapeutics 13: 196–200, 1972PubMedGoogle Scholar
  64. Lunde PKM, Rane A, Yaffe SJ, Lund L, Sjoqvist F. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clinical Pharmacology and Therapeutics 11: 846–855, 1970PubMedGoogle Scholar
  65. Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 5: 579–596, 1977PubMedCrossRefGoogle Scholar
  66. Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations in determining normalized phenytoin concentrations. Drug Intelligence and Clinical Pharmacy 23: 64–68, 1989Google Scholar
  67. McCauley DL, Tozer TN, Winter ME. Time for phenytoin concentration to peak: consequences of first-order and zero-order absorption. Therapeutic Drug Monitoring 11: 540–542, 1989PubMedCrossRefGoogle Scholar
  68. Morrow JI, Richens A. Disposition of anticonvulsants in childhood. Clinical Pharmacokinetics 17 (Suppl. 1): 89–104, 1989PubMedCrossRefGoogle Scholar
  69. Mucklow JC. The use of saliva in therapeutic drug monitoring. Therapeutic Drug Monitoring 4: 229–247, 1982CrossRefGoogle Scholar
  70. Mullen PW. Optimal phenytoin therapy: a new technique for individualizing dosage. Clinical Pharmacology and Therapeutics 23: 228–232, 1978PubMedGoogle Scholar
  71. Mullen PW, Foster RW. Comparative evaluation of six techniques for determining the Michaelis-Menten parameters relating phenytoin dose and steady-state serum concentrations. Journal of Pharmacy and Pharmacology 3: 100–104, 1979CrossRefGoogle Scholar
  72. Murphy JE, Bruni J, Stewart RB. Clinical utility of six methods of predicting phenytoin doses and plasma concentrations. American Journal of Hospital Pharmacy 38: 248–354, 1981Google Scholar
  73. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part 1). Clinical Pharmacokinetics 18: 37–60, 1990PubMedCrossRefGoogle Scholar
  74. Neuvonen PJ. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. Clinical Pharmacokinetics 4: 91–103, 1979PubMedCrossRefGoogle Scholar
  75. Paxton JW, Whiting B, Stephen KW. Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. British Journal of Clinical Pharmacology 4: 185–191, 1977PubMedCrossRefGoogle Scholar
  76. Perucca E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Therapeutic Drug Monitoring 2: 331–334, 1980PubMedGoogle Scholar
  77. Perucca E. Free level monitoring of antiepileptic drugs: clinical usefulness and case studies. Clinical Pharmacokinetics 9 (Suppl. 1): 71–78. 1984PubMedCrossRefGoogle Scholar
  78. Perucca E, Richens A. Antiepileptic drugs: clinical aspects. In Richens & Marks (Eds) Therapeutic drug monitoring, pp. 320–348, Churchill Livingstone, Edinburgh, 1981aGoogle Scholar
  79. Perucca E, Richens A. Drug interactions with phenytoin. Drugs 21: 120–137, 1981bPubMedCrossRefGoogle Scholar
  80. Peterson GM, McLean S, Aldous S, Von Witt RJ, Millingen K.S. Plasma protein binding of phenytoin in 100 epileptic patients. British Journal of Clinical Pharmacology 14: 298–300, 1982PubMedCrossRefGoogle Scholar
  81. Privitera MD, Homan RW, Ludden TM, Peck CC, Vasko MR. Clinical utility of a Bayesian dosing program for phenytoin. Therapeutic Drug Monitoring 11: 285–294, 1989PubMedCrossRefGoogle Scholar
  82. Rambeck B, Boenigk HE, Dunlop A, Mullen PW, Wadsworth J, et al. Predicting phenytoin dose — a revised nomogram. Therapeutic Drug Monitoring 1: 325–333, 1979PubMedCrossRefGoogle Scholar
  83. Rawson MD. Diphenylhydantoin intoxication and cerebrospinal fluid protein. Neurology 18: 1009–1011, 1968PubMedCrossRefGoogle Scholar
  84. Record KE, Rapp RP, Young AB, Kostenbauder HB. Oral phenytoin loading in adults: rapid achievement of therapeutic plasma levels. Annals of Neurology 5: 268–270, 1979PubMedCrossRefGoogle Scholar
  85. Reynolds EH. Early treatment and prognosis of epilepsy. Epilepsia 28: 97–106, 1987PubMedCrossRefGoogle Scholar
  86. Reynolds EH, Chadwick D, Galbraith AW. One drug (phenytoin) in the treatment of epilepsy. Lancet 1: 923–926, 1976PubMedCrossRefGoogle Scholar
  87. Reynolds EH, Shorvon SD, Galbraith AW, Chadwick D, Dellaportas CI, et al. Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia 22: 475–488, 1981PubMedCrossRefGoogle Scholar
  88. Reynolds EH, Trimble MR. Adverse neuropsychiatric effects of anticonvulsant drugs. Drugs 29: 570–581, 1985PubMedCrossRefGoogle Scholar
  89. Richens A. Clinical pharmacokinetics of phenytoin. Clinical Pharmacokinetics 4: 153–169, 1979PubMedCrossRefGoogle Scholar
  90. Rimmer EM, Buss DC, Routledge PA, Richens A. Should we routinely measure free plasma phenytoin concentration? British Journal of Clinical Pharmacology 17: 99–102, 1984PubMedCrossRefGoogle Scholar
  91. Ritschel WA, Alcorn GJ, Johnson RD, Rao S, Fogelson MH. Evaluation of a phenytoin dosage regimen design and adjustment computer program. Therapeutic Drug Monitoring 11: 437–449, 1989PubMedGoogle Scholar
  92. Rowland M. Protein binding and drug clearance. Clinical Pharmacokinetics 9 (Suppl. 1): 10–17, 1984PubMedCrossRefGoogle Scholar
  93. Sawchuk RJ, Pepin SM, Leppik IE, Gumnit RJ. Rapid and slow release phenytoin in epileptic patients at steady-state: assessment of relative bioavailability utilizing Michaelis-Menten parameters. Journal of Pharmacokinetics and Biopharmaceutics 10: 383–391, 1982PubMedCrossRefGoogle Scholar
  94. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobar-bital and carbamazepine. Archives of Neurology 43: 263–265, 1986PubMedCrossRefGoogle Scholar
  95. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 8: 553–571, 1980PubMedCrossRefGoogle Scholar
  96. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 9: 503–512, 1981PubMedCrossRefGoogle Scholar
  97. Sheiner LB, Beal SL, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clinical Pharmacology and Therapeutics 26: 294–305, 1979PubMedGoogle Scholar
  98. Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In Melmon & Morrelli (Eds) Clinical pharmacology, 2nd ed., pp. 71–109, McMillan Publishing, New York, 1978Google Scholar
  99. Shorvon SD, Reynolds EH. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. Journal of Neurology. Neurosurgery and Psychiatry 45: 620–626, 1982CrossRefGoogle Scholar
  100. Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clinical Pharmacology and Therapeutics 43: 345–353, 1988PubMedCrossRefGoogle Scholar
  101. Svensson CK, Woodruff MN, Lalka D. Influence of protein binding and use of unbound (free) drug concentrations. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., Applied Therapeutics Inc., Spokane, 1986Google Scholar
  102. Taylor JW, Murphy MJ, Berg MJ, Perry PJ, Lyon LW, et al. Phenytoin dosage requirements and pharmacokinetic variables. Clinical Pharmacy 2: 253–257, 1983PubMedGoogle Scholar
  103. Toscano JP, Jameson JP. Comparison of four single-point phenytoin dosage prediction techniques using computer-simulated pharmacokinetic values. Clinical Pharmacy 5: 396–402, 1986PubMedGoogle Scholar
  104. Troupin AS. The measurement of anticonvulsant agent levels. Annals of Internal Medicine 100: 854–858, 1984PubMedGoogle Scholar
  105. Troupin AS, Friel P. Anticonvulsant level in saliva, serum and cerebrospinal fluid. Epilepsia 16: 223–227, 1975PubMedCrossRefGoogle Scholar
  106. Troupin AS, Ojemann LM. Paradoxical intoxication — a complication of anticonvulsant administration. Epilepsia 16: 753–758, 1975PubMedCrossRefGoogle Scholar
  107. Vajda FJE, Aicardi J. Reassessment of the concept of a therapeutic range of anticonvulsant plasma levels. Developmental Medicine and Child Neurology 25: 660–671, 1983PubMedCrossRefGoogle Scholar
  108. Vo>zeh S, Follath F. Nomographic estimation of time to reach steady-state serum concentration during phenytoin therapy. European Journal of Clinical Pharmacology 17: 33–35, 1980CrossRefGoogle Scholar
  109. Vo>zeh S, Koelz A, Martin E, Magun H, Scollo-Lavizzari G, et al. Predictability of phenytoin serum levels by nomograms and clinicians. European Neurology 19: 345–352, 1980CrossRefGoogle Scholar
  110. Vo>zeh S, Muir K, Sheiner LB, Follath F. Predicting individual phenytoin dosage. Journal of Pharmacokinetics and Biopharmaceutics 9: 131–146, 1981CrossRefGoogle Scholar
  111. Vo>zeh S, Uematsu T, Aarons L, Maitre P, Landolt H, et al. Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus: a population pharmacokinetic study. Clinical Pharmacokinetics 14: 122–128, 1988CrossRefGoogle Scholar
  112. Wagner JG. Time to reach steady-state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics. Journal of Pharmacokinetics and Biopharmaceutics 6: 209–225, 1978PubMedCrossRefGoogle Scholar
  113. Wagner JG. New and simple method to predict dosage of drugs obeing simple Michaelis-Menten elimination kinetics and to distinguish such kinetics from simple first order and from parallel Michaelis-Menten and first order kinetics. Therapeutic Drug Monitoring 7: 377–386, 1985PubMedCrossRefGoogle Scholar
  114. Wenk M, Vo>zeh S, Follath F. Serum level monitoring of antibacterial drugs: a review. Clinical Pharmacokinetics 9: 475–492, 1984PubMedCrossRefGoogle Scholar
  115. Wing DS, Duff HJ. The impact of a therapeutic drug monitoring program for phenytoin. Therapeutic Drug Monitoring 11: 32–37, 1989PubMedCrossRefGoogle Scholar
  116. Winter M, Tozer TN. Phenytoin. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 493–539, Applied Therapeutics Inc., Spokane, 1986Google Scholar
  117. Woo E, Chan YM, Yu YL, Chan W, Huang CY. If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 29: 129–139, 1988PubMedCrossRefGoogle Scholar
  118. Yuen GJ, Latimer PT, Littlefield LC, Mackey RW. Phenytoin dosage predictions in pediatric patients. Clinical Pharmacokinetics 16: 254–260, 1989PubMedCrossRefGoogle Scholar
  119. Yuen GJ, Taylor JW, Ludden TM, Murphy MJ. Predicting phenytoin dosages using Bayesian feedback: a comparison with other methods. Therapeutic Drug Monitoring 5: 437–441, 1983PubMedCrossRefGoogle Scholar
  120. Yukawa E, Higuchi S, Aoyama T. Evaluation of single-point phenytoin dosage prediction methods in pediatric patients. Journal of Pharmacobio-Dynamics 11: 736–743, 1988PubMedCrossRefGoogle Scholar
  121. Zaccara G, Messori A, Muscas GC, Albani F, Baruzzi A, et al. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi-center evaluation in 282 patients with epilepsy. Epilepsy Research 3: 253–261, 1989PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1990

Authors and Affiliations

  • Marc Levine
    • 1
    • 2
  • Tom Chang
    • 1
    • 2
  1. 1.Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada
  2. 2.Departments of Medicine and PharmacyUniversity HospitalVancouverCanada

Personalised recommendations